Opsona Therapeutics works with leading partners
Developing and maintaining partnerships is a top priority at Opsona Therapeutics.
Opsona's partnerships with leading international biopharmaceutical companies such as CSL, Organon and Wyeth and reflect our ability to deliver and the significant interest in our unique approach and technology.
CSL Limited: 2009 -
Vaccine Adjuvant R&D Collaboration with global specialty biopharmaceutical company CSL Limited. Opsona's proprietary technology OpsoVacTM - Targeting Infectious Diseases and Oncology.
Merck: 2008 -
Strategic Research Cluster with Merck, Trinity College Dublin and National University of Ireland (Maynooth). Objective: to identify New Stimulators of Three Classes of Receptors of Innate Immunity, TLRs, NLRs, and RLRs.
Wyeth Pharmaceuticals (a division of Pfizer): 2006 -
Discovery of New Chemical Entities and Biologics in the TLR space for the Treatment of Autoimmune and Inflammatory Diseases.
Partnering opportunities
Opsona will continue to form appropriate partnerships with leading international pharmaceutical companies and researchers for collaboration. Email new opportunities and requests for further information to info@opsona.com
We are seeking to license our OPN-501 small molecule colon targeted Pro-Drug platform for Inflammatory Bowel Diseases, and to partner OpsoVacTM platform ( for Increased Efficacy and Antigen Sparing of Vaccines & Immunotherapeutics) with companies who ideally have access to TLR agonists.